{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:43:06Z","timestamp":1790959386429,"version":"4.1.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer is still incurable. Age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase level, and prognostic indications including increased expression of Ki-67 and presence of TP53 mutation, are symbols of poor outcome. Advanced immunotherapy using chimeric antigen receptor (CAR)-T cells is advantageous for patients suffering from B-cell malignancies and MCL. Targeting B-cell antigens on the cell surface is a feasible approach in re-occurring (R\/R) MCL because of significant responses obtained in other B-cell cancers. USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy to be used in patients with MCL who have not responded to previous treatments or have relapsed. The FDA approved this new treatment depending on the outcomes of the ZUMA-2 clinical trial. Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CAR T-cell therapy. This review is a brief synopsis of the development of CAR T-cell therapy for MCL.<\/jats:p>","DOI":"10.1186\/s12943-023-01755-5","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T07:09:37Z","timestamp":1680592177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["CAR T-Cell therapy for the management of mantle cell lymphoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Zoufang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-8597","authenticated-orcid":false,"given":"Vivek P.","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashri","family":"Bezbaruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Dhamne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"crossref","unstructured":"Armitage JO, Longo DL. Mantle-Cell Lymphoma. Hardin CC, editor. Massachusetts Medical Society; 2022;386:2495\u2013506.\u00a0101056\/NEJMra2202672.","DOI":"10.1056\/NEJMra2202672"},{"key":"1755_CR2","first-page":"226","volume":"3","author":"JS Burke","year":"2012","unstructured":"Burke JS. Lymphoid Lesions. Pathology. 2012;3:226\u201345 (Philadelphia, Pa). W.B. Saunders.","journal-title":"Pathology"},{"key":"1755_CR3","doi-asserted-by":"crossref","unstructured":"Pieters T, T\u2019Sas S, Vanhee S, Almeida A, Driege Y, Roels J, et al. Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice. Journal of Experimental Medicine. Rockefeller University Press; 2021;218.","DOI":"10.1084\/jem.20202280"},{"key":"1755_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/PAI.0b013e31825d550a","volume":"21","author":"SD Boyd","year":"2013","unstructured":"Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21:116\u201331.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.V85.6.1570.bloodjournal8561570","volume":"85","author":"GH Segal","year":"1995","unstructured":"Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan RC. CD5-Expressing B-Cell Non-Hodgkin\u2019s Lymphomas With bcl-1 Gene Rearrangement Have a Relatively Homogeneous Immunophenotype and Are Associated With an Overall Poor Prognosis. Blood. 1995;85:1570\u20139.","journal-title":"Blood"},{"key":"1755_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","volume":"154","author":"JY Li","year":"1999","unstructured":"Li JY, Gaillard F, Moreau A, Harousseau JL, Laboisse C, Milpied N, et al. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol. 1999;154:1449\u201352.","journal-title":"Am J Pathol"},{"key":"1755_CR7","doi-asserted-by":"crossref","unstructured":"Gao D, Liu Z. Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge. Biomarker research. England; 2019;7:11.","DOI":"10.1186\/s40364-019-0162-2"},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","volume":"106","author":"K Fu","year":"2005","unstructured":"Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315\u201321.","journal-title":"Blood"},{"key":"1755_CR9","first-page":"26","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood American Society of Hematology. 2011;117:26\u201338.","journal-title":"Blood American Society of Hematology"},{"key":"1755_CR10","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/cancers12082120","volume":"12","author":"D Malarikova","year":"2020","unstructured":"Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K, et al. Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers. 2020;12:2120.","journal-title":"Cancers"},{"key":"1755_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022\u2014A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638\u201356.","journal-title":"Am J Hematol"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MOH.0000000000000434","volume":"25","author":"R Beekman","year":"2018","unstructured":"Beekman R, Amador V, Campo E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. 2018;25:299\u2013306.","journal-title":"Curr Opin Hematol"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.3390\/ijms22126247","volume":"22","author":"L Sadeghi","year":"2021","unstructured":"Sadeghi L, Wright AP. Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape. Int J Mol Sci. 2021;22:6247.","journal-title":"Int J Mol Sci"},{"key":"1755_CR14","unstructured":"CAR T Cells: Engineering Immune Cells to Treat Cancer - National Cancer Institute."},{"key":"1755_CR15","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1002\/cnr2.1590","volume":"5","author":"VS Radhakrishnan","year":"2022","unstructured":"Radhakrishnan VS, Lokireddy P, Parihar M, Prakash PS, Menon H. Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. Cancer Rep. 2022;5:e1590.","journal-title":"Cancer Rep"},{"key":"1755_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/cncr.11096","volume":"97","author":"JE Romaguera","year":"2003","unstructured":"Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97:586\u201391.","journal-title":"Cancer"},{"key":"1755_CR17","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","volume":"24","author":"CY Cheah","year":"2013","unstructured":"Cheah CY, George A, Gin\u00e9 E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Annals of Oncology Elsevier. 2013;24:2119\u201323.","journal-title":"Annals of Oncology Elsevier"},{"key":"1755_CR18","unstructured":"Lynch DT, Koya S, Acharya U. Mantle Cell Lymphoma. [Updated 2022 Feb 1]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536985\/."},{"key":"1755_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematology. 2019;94:710\u201325.","journal-title":"Am J Hematology"},{"key":"1755_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","volume":"13","author":"W Hanel","year":"2020","unstructured":"Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13:79.","journal-title":"J Hematol Oncol"},{"key":"1755_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511\u20138.","journal-title":"J Clin Oncol."},{"key":"1755_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344\u20139 Wiley & Sons, Ltd.","journal-title":"Br J Haematol"},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104:e68.","journal-title":"Haematologica"},{"key":"1755_CR24","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","volume":"8","author":"YW Jeon","year":"2019","unstructured":"Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, et al. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med. 2019;8:6860\u201370.","journal-title":"Cancer Med"},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1093\/annonc\/11.suppl_1.S123","volume":"11","author":"M Ghielmini","year":"2000","unstructured":"Ghielmini M, Hsu Schmitz SF, B\u00fcrki K, Pichert G, Betticher DC, Stupp R, et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Annals of Oncology Elsevier. 2000;11:S123\u20136.","journal-title":"Annals of Oncology Elsevier"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","volume":"89","author":"LH Argatoff","year":"1997","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases. Blood. 1997;89:2067\u201378.","journal-title":"Blood"},{"key":"1755_CR27","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D\u2019Amore F, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124:1288\u201395.","journal-title":"Blood"},{"key":"1755_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/hon.146_2630","volume":"37","author":"M Wang","year":"2019","unstructured":"Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, et al. Results from the safety run-in period of the sympatico study evaluating ibrutinib in combination with venetoclax in patients with relapsed\/refractory mantle cell lymphoma. Hematol Oncol. 2019;37:333\u20135.","journal-title":"Hematol Oncol"},{"key":"1755_CR29","first-page":"5119","volume":"18","author":"W Zhang","year":"2019","unstructured":"Zhang W, Zhu J, He X, Liu X, Li J, Li W, et al. Exosome complex genes mediate RNA degradation and predict survival in mantle cell lymphoma. Oncology letters Greece. 2019;18:5119\u201328.","journal-title":"Oncology letters Greece"},{"key":"1755_CR30","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","volume":"108","author":"H Dai","year":"2016","unstructured":"Dai H, Wang Y, Lu X, Han W. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst. 2016;108:djv439.","journal-title":"J Natl Cancer Inst"},{"key":"1755_CR31","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1755_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101 Elsevier Ltd.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1755_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017;34:2232\u201373.","journal-title":"Adv Ther"},{"key":"1755_CR34","first-page":"456","volume":"17","author":"M Szcze\u015bniak","year":"2013","unstructured":"Szcze\u015bniak M, Armatys A, Kurzawa R, Kandzia T, Kozio\u0142 D, Frankiewicz A, et al. Autologous stem cell transplantation for mantle cell lymphoma - single centre experience. Contemp Oncol (Pozn). 2013;17:456\u20139.","journal-title":"Contemp Oncol (Pozn)"},{"key":"1755_CR35","doi-asserted-by":"crossref","unstructured":"Li H, Fu Q, Muluh AT, Shinge AUS, Fu S, Wu J. The Application of Nanotechnology in Immunotherapy based Combinations for Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery. 2023. p. 53\u201365.","DOI":"10.2174\/1574892817666220308090954"},{"key":"1755_CR36","doi-asserted-by":"crossref","unstructured":"Chavda VP, Vihol D, Mehta B, Shah D, Patel M, Vora LK, et al. Phytochemical-loaded liposomes for anticancer therapy: an updated review. Nanomedicine. Future Medicine; 2022;.","DOI":"10.2217\/nnm-2021-0463"},{"key":"1755_CR37","doi-asserted-by":"crossref","unstructured":"Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu Z-X, Chen Z-S, et al. Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges . Frontiers in Oncology . 2022.","DOI":"10.3389\/fonc.2022.867655"},{"key":"1755_CR38","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"1755_CR39","doi-asserted-by":"publisher","unstructured":"Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, et al. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. American Journal of Hematology. John Wiley & Sons, Ltd; 2015 [cited 2023 Feb 14];90:E111\u20136. Available from: https:\/\/doi.org\/10.1002\/ajh.23996.","DOI":"10.1002\/ajh.23996"},{"key":"1755_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N. The Lancet Elsevier. 2016;388:565\u201375.","journal-title":"The Lancet Elsevier"},{"key":"1755_CR41","first-page":"858","volume":"4","author":"RW Merryman","year":"2020","unstructured":"Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, et al. Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood. 2020;4:858\u201367.","journal-title":"Blood"},{"key":"1755_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med"},{"key":"1755_CR43","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","volume":"5","author":"CW Eskelund","year":"2020","unstructured":"Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, R\u00e4ty R, Gjerdrum LMR, et al. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. HemaSphere. 2020;5:e510\u2013e510.","journal-title":"HemaSphere"},{"key":"1755_CR44","unstructured":"ECOG-ACRIN EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by."},{"key":"1755_CR45","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34:1386\u201395.","journal-title":"J Clin Oncol"},{"key":"1755_CR46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, Von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet Elsevier. 2013;381:1203\u201310.","journal-title":"The Lancet Elsevier"},{"key":"1755_CR47","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood.V124.21.4407.4407","volume":"124","author":"MJ Rummel","year":"2014","unstructured":"Rummel MJ, Maschmeyer G, Ganser A, Heider A, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) \u2013 7 Year Updated Results from the StiL NHL1 Study. Blood. 2014;124:4407.","journal-title":"Blood"},{"key":"1755_CR48","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Van Der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"1755_CR49","doi-asserted-by":"crossref","unstructured":"Vora AP, Patel R, Dharamsi A. Bortezomib \u2013 First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery. 2020. p. 113\u201331.","DOI":"10.2174\/1574892815666200401113805"},{"key":"1755_CR50","unstructured":"Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study. Blood. Content Repository Only!; 2017;130:154."},{"key":"1755_CR51","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1634\/theoncologist.2017-0470","volume":"23","author":"H Ye","year":"2018","unstructured":"Ye H, Desai A, Zeng D, Romaguera J, Wang ML. Frontline Treatment for Older Patients with Mantle Cell Lymphoma. Oncologist. 2018;23:1337\u201348.","journal-title":"Oncologist"},{"key":"1755_CR52","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers12061565","volume":"12","author":"G Rou\u00e9","year":"2020","unstructured":"Rou\u00e9 G, Sola B. Management of Drug Resistance in Mantle Cell Lymphoma. Cancers. 2020;12:1565.","journal-title":"Cancers"},{"key":"1755_CR53","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology Elsevier. 2009;20:520\u20135.","journal-title":"Annals of Oncology Elsevier"},{"issue":"3822","key":"1755_CR54","first-page":"9","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(3822):9.","journal-title":"J Clin Oncol"},{"key":"1755_CR55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","volume":"14","author":"J Singh","year":"2010","unstructured":"Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010;14:475\u201380 (Elsevier Current Trends).","journal-title":"Curr Opin Chem Biol"},{"key":"1755_CR56","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Eng J Med. 2018;378:1211\u201323 (Massachusetts Medical Society).","journal-title":"N Eng J Med"},{"key":"1755_CR57","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189:684\u20138 (John Wiley & Sons, Ltd).","journal-title":"Br J Haematol"},{"key":"1755_CR58","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35:826 (American Society of Clinical Oncology).","journal-title":"J Clin Oncol"},{"key":"1755_CR59","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","volume":"123","author":"V Fresquet","year":"2014","unstructured":"Fresquet V, Rieger M, Carolis C, Garc\u00eda-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123:4111\u20139 (American Society of Hematology).","journal-title":"Blood"},{"key":"1755_CR60","first-page":"2026","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Taylor & Francis. 2017;58:2026\u201339.","journal-title":"Taylor & Francis"},{"key":"1755_CR61","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjh.15723","volume":"184","author":"S Rule","year":"2019","unstructured":"Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphom. Br J Haematol. 2019;184:999\u20131005 John Wiley & Sons, Ltd.","journal-title":"Br J Haematol"},{"key":"1755_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","volume":"2","author":"I Barista","year":"2001","unstructured":"Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncology. 2001;2:141\u20138 (Elsevier).","journal-title":"Lancet Oncology"},{"key":"1755_CR63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","volume":"21","author":"A Mian","year":"2021","unstructured":"Mian A, Hill BT. Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma. Expert Opin Biol Ther. 2021;21:435\u201341.","journal-title":"Expert Opin Biol Ther"},{"key":"1755_CR64","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1755_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.imlet.2019.06.002","volume":"212","author":"M Zabel","year":"2019","unstructured":"Zabel M, Tauber PA, Pickl WF. The making and function of CAR cells. Immunol lett. 2019;212:53.","journal-title":"Immunol lett"},{"key":"1755_CR66","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci. 1993;90:720\u20134.","journal-title":"Proc Natl Acad Sci"},{"key":"1755_CR67","doi-asserted-by":"publisher","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 1989 [cited 2023 Feb 14];86:10024\u20138. Available from: https:\/\/doi.org\/10.1073\/pnas.86.24.10024.","DOI":"10.1073\/pnas.86.24.10024"},{"key":"1755_CR68","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological reviews England. 2019;290:127\u201347.","journal-title":"Immunological reviews England"},{"key":"1755_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1358\/dot.2022.58.3.3381592","volume":"58","author":"W Tu","year":"2022","unstructured":"Tu W, Xiao Y, Wang Y, Luo R, Chen Z-S. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: a review of recent advances. Drugs of today (Barc). 2022;58:117\u201332 Spain.","journal-title":"Drugs of today (Barc)"},{"key":"1755_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2478\/ahp-2020-0002","volume":"51","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski J. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematol Pol. 2020;51:2\u20135.","journal-title":"Acta Haematol Pol"},{"key":"1755_CR71","doi-asserted-by":"crossref","unstructured":"Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Frontiers in immunology. Frontiers Media S.A.; 2020;11:702.","DOI":"10.3389\/fimmu.2020.00702"},{"key":"1755_CR72","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov"},{"key":"1755_CR73","doi-asserted-by":"crossref","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology. Frontiers Media SA; 2014;5.","DOI":"10.3389\/fphar.2014.00235"},{"key":"1755_CR74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83\u201390 John Wiley & Sons, Ltd.","journal-title":"Immunol Rev"},{"key":"1755_CR75","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-018-0676-3","volume":"11","author":"Y Zou","year":"2018","unstructured":"Zou Y, Xu W, Li J. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. J Hematol Oncol. 2018;11:130 BioMed Central.","journal-title":"J Hematol Oncol"},{"key":"1755_CR76","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Clin Cancer Res. 2019;25:1142\u20136.","journal-title":"Clin Cancer Res"},{"key":"1755_CR77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. The Lancet Oncology Lancet Oncol. 2019;20:31\u201342.","journal-title":"The Lancet Oncology Lancet Oncol"},{"key":"1755_CR78","unstructured":"FDA approves axicabtagene ciloleucel for large B-cell lymphoma | FDA."},{"key":"1755_CR79","unstructured":"FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma | FDA."},{"key":"1755_CR80","unstructured":"U.S. FDA Approves Kite\u2019s TecartusTM, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma."},{"key":"1755_CR81","doi-asserted-by":"publisher","unstructured":"Banerjee R, Prasad V. Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review. JAMA Network Open. 2021 [cited 2023 Feb 15];4:e2115668\u2013e2115668. Available from: https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.15668.","DOI":"10.1001\/jamanetworkopen.2021.15668"},{"key":"1755_CR82","doi-asserted-by":"crossref","first-page":"204062072210807","DOI":"10.1177\/20406207221080738","volume":"13","author":"B Tbakhi","year":"2022","unstructured":"Tbakhi B, Reagan PM. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Therapeutic advances in hematology SAGE Publications. 2022;13:20406207221080736\u201320406207221080736.","journal-title":"Therapeutic advances in hematology SAGE Publications"},{"key":"1755_CR83","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4049\/jimmunol.1701155","volume":"200","author":"S Srivastava","year":"2018","unstructured":"Srivastava S, Riddell SR. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. J Immunol. 2018;200:459\u201368 (Baltimore, Md\u202f: 1950).","journal-title":"J Immunol"},{"key":"1755_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica Ferrata Storti Foundation. 2020;105:297\u2013316.","journal-title":"Haematologica Ferrata Storti Foundation"},{"key":"1755_CR85","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2016","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2016;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1755_CR86","doi-asserted-by":"crossref","unstructured":"Strachan BC, Xia H, V\u00f6r\u00f6s E, Gifford SC, Shevkoplyas SS. Improved expansion of T cells in culture when isolated with an equipment-free, high-throughput, flow-through microfluidic module versus traditional density gradient centrifugation. Cytotherapy. 2019\/01\/16 ed. 2019;21:234\u201345.","DOI":"10.1016\/j.jcyt.2018.12.004"},{"key":"1755_CR87","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015 Nature Publishing Group.","journal-title":"Mol Ther Oncolytics"},{"key":"1755_CR88","doi-asserted-by":"crossref","unstructured":"Szopa IM, Granica M, Bujak JK, \u0141ab\u0119d\u017a A, B\u0142aszczyk M, Paulos CM, et al. Effective Activation and Expansion of Canine Lymphocytes Using a Novel Nano-Sized Magnetic Beads Approach . Frontiers in Immunology . 2021.","DOI":"10.3389\/fimmu.2021.604066"},{"key":"1755_CR89","doi-asserted-by":"crossref","unstructured":"Riddell SR, Sommermeyer D, Berger C, Liu L (Steven), Balakrishnan A, Salter A, et al. Adoptive Therapy With Chimeric Antigen Receptor\u2013Modified T Cells of Defined Subset Composition. The Cancer Journal. Cancer J; 2014;20:141\u20134.","DOI":"10.1097\/PPO.0000000000000036"},{"key":"1755_CR90","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99\u2013115.","journal-title":"Nat Rev Drug Discov"},{"key":"1755_CR91","first-page":"1","volume-title":"Romina S","author":"A Anto\u00f1ana-vildosola","year":"2022","unstructured":"Anto\u00f1ana-vildosola A. Romina S. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment; 2022. p. 1\u201325."},{"key":"1755_CR92","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee C-CR, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335.","journal-title":"J Exp Med"},{"key":"1755_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"E Lanitis","year":"2015","unstructured":"Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55\u201363.","journal-title":"Curr Opin Immunol"},{"key":"1755_CR94","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","volume":"120","author":"D Chinnasamy","year":"2010","unstructured":"Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120:3953\u201368 American Society for Clinical Investigation.","journal-title":"J Clin Invest"},{"key":"1755_CR95","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","volume":"18","author":"D Chinnasamy","year":"2012","unstructured":"Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice. Clinical Cancer Research NIH Public Access. 2012;18:1672\u201383.","journal-title":"Clinical Cancer Research NIH Public Access"},{"key":"1755_CR96","doi-asserted-by":"publisher","unstructured":"Andrea AE, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Frontiers in Immunology [Internet]. 2022;13. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2022.830292.","DOI":"10.3389\/fimmu.2022.830292"},{"key":"1755_CR97","doi-asserted-by":"crossref","unstructured":"Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Current problems in cancer. 2021\/12\/25 ed. United States; 2022;46:100826.","DOI":"10.1016\/j.currproblcancer.2021.100826"},{"key":"1755_CR98","doi-asserted-by":"publisher","unstructured":"Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood [Internet]. 2021 [cited 2023 Feb 15];138:11\u201322. Available from: https:\/\/doi.org\/10.1182\/blood.2020009098.","DOI":"10.1182\/blood.2020009098"},{"key":"1755_CR99","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","volume":"9","author":"C Tomuleasa","year":"2018","unstructured":"Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, et al. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2018;9:239 Frontiers Media S.A.","journal-title":"Front Immunol"},{"key":"1755_CR100","doi-asserted-by":"crossref","unstructured":"Akbari P, Katsarou A, Daghighian R, van Mil LWHG, Huijbers EJM, Griffioen AW, et al. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochimica et biophysica acta Reviews on cancer. Biochim Biophys Acta Rev Cancer; 2022;1877.","DOI":"10.1016\/j.bbcan.2022.188701"},{"key":"1755_CR101","first-page":"241","volume":"134","author":"JS Abramson","year":"2019","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed\/Refractory (R\/R) Large B Cell Lymphomas. Blood American Society of Hematology. 2019;134:241\u2013241.","journal-title":"Blood American Society of Hematology"},{"key":"1755_CR102","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/jcm10061207","volume":"10","author":"DA Bond","year":"2021","unstructured":"Bond DA, Martin P, Maddocks KJ. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. J Clin Med. 2021;10:1207.","journal-title":"J Clin Med"},{"key":"1755_CR103","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","volume":"97","author":"C Renner","year":"2012","unstructured":"Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F, et al. A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012;97:1085\u201391.","journal-title":"Haematologica"},{"key":"1755_CR104","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","volume":"34","author":"JS Abramson","year":"2020","unstructured":"Abramson JS. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Transfusion medicine reviews Transfus Med Rev. 2020;34:29\u201333.","journal-title":"Transfusion medicine reviews Transfus Med Rev"},{"key":"1755_CR105","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2020.00849","volume":"10","author":"C Vitale","year":"2020","unstructured":"Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol. 2020;10:849.","journal-title":"Front Oncol"},{"key":"1755_CR106","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. The Lancet. 2022;399:2294\u2013308.","journal-title":"The Lancet"},{"key":"1755_CR107","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clml.2020.11.005","volume":"21","author":"S Kambhampati","year":"2021","unstructured":"Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, et al. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021;21:246-256.e2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1755_CR108","doi-asserted-by":"publisher","first-page":"12722","DOI":"10.1182\/blood-2022-156635","volume":"140","author":"W Lei","year":"2022","unstructured":"Lei W, Ai Z, Liu H, Yang C, Wei C, Guo S, et al. Safety and Feasibility of Anti-CD19 CAR-T Expressing IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood. 2022;140:12722\u201312722.","journal-title":"Blood"},{"key":"1755_CR109","doi-asserted-by":"publisher","unstructured":"Reagan PM, Friedberg JW. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncology. Future Medicine; 2021 [cited 2023 Feb 14];17:1269\u201383. Available from: https:\/\/doi.org\/10.2217\/fon-2020-0291.","DOI":"10.2217\/fon-2020-0291"},{"key":"1755_CR110","doi-asserted-by":"publisher","unstructured":"Zhou H, Luo Y, Zhu S, Wang X, Zhao Y, Ou X, et al. The efficacy and safety of anti-CD19\/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. BMC Cancer. 2018;18:929. Available from: https:\/\/doi.org\/10.1186\/s12885-018-4817-4.","DOI":"10.1186\/s12885-018-4817-4"},{"key":"1755_CR111","doi-asserted-by":"publisher","unstructured":"Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, et al. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy. Elsevier; 2022 [cited 2023 Feb 14];24:767\u201373. Available from: https:\/\/doi.org\/10.1016\/j.jcyt.2022.03.011.","DOI":"10.1016\/j.jcyt.2022.03.011"},{"key":"1755_CR112","unstructured":"Definition of autologous anti-CD19CAR-4\u20131BB-CD3zeta-EGFRt-expressing T lymphocytes - NCI Drug Dictionary - NCI. 2011 [cited 2023 Feb 15]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/autologous-anti-cd19car-4-1bb-cd3zeta-egfrt-expressing-t-lymphocytes."},{"key":"1755_CR113","unstructured":"Immuno-Oncology. CRISPR. [cited 2023 Feb 15]. Available from: https:\/\/crisprtx.com\/programs\/immuno-oncology."},{"key":"1755_CR114","unstructured":"Mustang Bio Announces Phase 1\/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom\u2019s Macroglobulinemia. Mustang Bio, Inc. 2022 [cited 2023 Feb 15]. Available from: https:\/\/ir.mustangbio.com\/news-events\/press-releases\/detail\/150\/mustang-bio-announces-phase-12-clinical-trial-data-of."},{"key":"1755_CR115","doi-asserted-by":"publisher","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. The Lancet Oncology. Elsevier; 2022 [cited 2023 Feb 14];23:1066\u201377. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(22)00339-4.","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"1755_CR116","unstructured":"Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma (NHL) [Internet]. 2022 [cited 2023 Feb 15]. Available from: https:\/\/www.businesswire.com\/news\/home\/20221103005397\/en\/Adicet-Bio-Reports-ASH-Abstract-Data-from-Ongoing-ADI-001-Phase-1-Trial-in-Relapsed-or-Refractory-Aggressive-B-Cell-Non-Hodgkin%E2%80%99s-Lymphoma-NHL."},{"key":"1755_CR117","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy AH, Locke FL, Jacobson CA, Hill BT, et al. One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed\/Refractory Mantle Cell Lymphoma. Blood. Content Repository Only!; 2020;136:20\u20132.","DOI":"10.1182\/blood-2020-136382"},{"key":"1755_CR118","unstructured":"Kite AGC. ZUMA-2 Trial for TECARTUS\u00ae (brexucabtagene autoleucel). 2022 [cited 2022 Nov 28]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02601313."},{"key":"1755_CR119","doi-asserted-by":"publisher","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. Massachusetts Medical Society; 2014 [cited 2023 Feb 14];371:1507\u201317. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1407222.","DOI":"10.1056\/NEJMoa1407222"},{"key":"1755_CR120","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-136158","volume":"136","author":"ML Palomba","year":"2020","unstructured":"Palomba ML, Gordon LI, Siddiqi T, Abramson JS, Kamdar M, Lunning MA, et al. Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. Blood. 2020;136:10\u20131 (American Society of Hematology).","journal-title":"Blood"},{"key":"1755_CR121","doi-asserted-by":"crossref","unstructured":"Li T, Zhang Y, Peng D, Mao X, Zhou X, Zhou J. A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. J Immunother Cancer. 2019;7:51. Available from: http:\/\/jitc.bmj.com\/content\/7\/1\/51.abstract.","DOI":"10.1186\/s40425-019-0529-9"},{"key":"1755_CR122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1755_CR123","doi-asserted-by":"crossref","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nature Reviews Clinical Oncology. Springer US; 2019;16:372\u201385.","DOI":"10.1038\/s41571-019-0184-6"},{"key":"1755_CR124","doi-asserted-by":"crossref","unstructured":"Tumor Antigen Escape from CAR T-cell Therapy | Cancer Discovery | American Association for Cancer Research. [cited 2023 Feb 2]. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/10\/1219\/6227\/Tumor-Antigen-Escape-from-CAR-T-cell.","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"1755_CR125","unstructured":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy | Nature Reviews Clinical Oncology. [cited 2023 Feb 2]. Available from: https:\/\/www.nature.com\/articles\/s41571-019-0297-y."},{"key":"1755_CR126","doi-asserted-by":"publisher","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Khoshtinat Nikkhoi S. Strategies for Dodging the Obstacles in CAR T Cell Therapy. Frontiers in Oncology. 2021;11. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2021.627549.","DOI":"10.3389\/fonc.2021.627549"},{"key":"1755_CR127","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011 Official journal of the American Society of Gene & Cell Therapy.","journal-title":"Mol Ther Oncolytics"},{"key":"1755_CR128","doi-asserted-by":"publisher","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015 [cited 2023 Feb 15];125:4017\u201323. Available from: https:\/\/doi.org\/10.1182\/blood-2014-12-580068.","DOI":"10.1182\/blood-2014-12-580068"},{"key":"1755_CR129","doi-asserted-by":"publisher","unstructured":"Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A, et al. An oxygen sensitive self-decision making engineered CAR T-cell. Scientific Reports. 2017;7:39833. Available from: https:\/\/doi.org\/10.1038\/srep39833.","DOI":"10.1038\/srep39833"},{"key":"1755_CR130","doi-asserted-by":"crossref","unstructured":"Glycan-directed CAR-T cells | Glycobiology | Oxford Academic. [cited 2023 Feb 2]. Available from: https:\/\/academic.oup.com\/glycob\/article\/28\/9\/656\/4821293?login=false.","DOI":"10.1093\/glycob\/cwy008"},{"key":"1755_CR131","doi-asserted-by":"publisher","unstructured":"Frontiers | Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. [cited 2023 Feb 2]. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2018.02268\/full.","DOI":"10.3389\/fimmu.2018.02268\/full"},{"key":"1755_CR132","doi-asserted-by":"publisher","unstructured":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer | Journal for ImmunoTherapy of Cancer. [cited 2023 Feb 2]. Available from: https:\/\/jitc.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40425-017-0222-9.","DOI":"10.1186\/s40425-017-0222-9"},{"key":"1755_CR133","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1755_CR134","doi-asserted-by":"crossref","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. Journal of hematology & oncology. J Hematol Oncol; 2018;11.","DOI":"10.1186\/s13045-018-0571-y"},{"key":"1755_CR135","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. \u00a0ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1755_CR136","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","volume":"5","author":"CS Tam","year":"2021","unstructured":"Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood advances Blood Adv. 2021;5:2577\u201385.","journal-title":"Blood advances Blood Adv"},{"key":"1755_CR137","unstructured":"NCI Staff. CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma - National Cancer Institute. NCI. 2022 [cited 2022 Nov 28]. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-brexucabtagene-mantle-cell-lymphoma."},{"key":"1755_CR138","first-page":"832","volume":"324","author":"R Voelker","year":"2020","unstructured":"Voelker R. New FDA-EPA Protocol Covers Agricultural Water Safety. JAMA American Medical Association. 2020;324:832\u2013832.","journal-title":"JAMA American Medical Association"},{"key":"1755_CR139","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","volume":"110","author":"W Munakata","year":"2019","unstructured":"Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, et al. Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer science Cancer Sci. 2019;110:1686\u201394.","journal-title":"Cancer science Cancer Sci"},{"key":"1755_CR140","doi-asserted-by":"publisher","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai N. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Front Immunol. 2021;12:693016 Frontiers Media S.A.","journal-title":"Front Immunol"},{"key":"1755_CR141","unstructured":"ZUMA-2 Trial and Implications For CAR T in MCL. [cited 2022 Mar 22]. Available from: https:\/\/www.targetedonc.com\/view\/zuma-2-trial-and-implications-for-car-t-in-mcl."},{"key":"1755_CR142","unstructured":"CAR T Cells: Timeline of Progress | Memorial Sloan Kettering Cancer Center. [cited 2022 Mar 22]. Available from: https:\/\/www.mskcc.org\/timeline\/car-t-timeline-progress."},{"key":"1755_CR143","doi-asserted-by":"crossref","unstructured":"Wang M, Jain P, Chi TL, Chen SE, Heimberger A, Weathers SP, et al. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. Journal for ImmunoTherapy of Cancer. BMJ Publishing Group; 2020;8.","DOI":"10.1136\/jitc-2020-001114"},{"key":"1755_CR144","doi-asserted-by":"crossref","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal 2021 11:4. Nature Publishing Group; 2021;11:1\u201311.","DOI":"10.1038\/s41408-021-00459-7"},{"key":"1755_CR145","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","volume":"8","author":"MC Milone","year":"2018","unstructured":"Milone MC, Bhoj VG. The Pharmacology of T Cell Therapies. Mol Ther Methods Clin Dev. 2018;8:210\u201321.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1755_CR146","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res. 2015;75:3596\u2013607 American Association for Cancer Research.","journal-title":"Cancer Res"},{"key":"1755_CR147","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med Nature Publishing Group. 2019;25:947\u201353.","journal-title":"Nat Med Nature Publishing Group"},{"key":"1755_CR148","first-page":"2191","volume":"31","author":"D Sommermeyer","year":"2017","unstructured":"Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia Nature Publishing Group. 2017;31:2191\u20139.","journal-title":"Leukemia Nature Publishing Group"},{"key":"1755_CR149","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory, Aggressive Non-Hodgkin Lymphoma (NHL). Blood. 2017;130:1547.","journal-title":"Blood"},{"key":"1755_CR150","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344 Massachusetts Medical Society.","journal-title":"N Engl J Med"},{"key":"1755_CR151","unstructured":"Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies - PubMed. [cited 2023 Feb 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31764168\/."},{"key":"1755_CR152","doi-asserted-by":"crossref","unstructured":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts | Blood | American Society of Hematology. [cited 2023 Feb 1]. Available from: https:\/\/ashpublications.org\/blood\/article\/133\/7\/697\/260575\/GM-CSF-inhibition-reduces-cytokine-release.","DOI":"10.1182\/blood-2018-10-881722"},{"key":"1755_CR153","unstructured":"Granulocyte\u2013macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators - Journal of Biological Chemistry. [cited 2023 Feb 1]. Available from: https:\/\/www.jbc.org\/article\/S0021-9258(20)35503-4\/fulltext."},{"key":"1755_CR154","unstructured":"Disruption of a\u00a0self-amplifying catecholamine loop reduces cytokine release syndrome | Nature. [cited 2023 Feb 1]. Available from: https:\/\/www.nature.com\/articles\/s41586-018-0774-y."},{"key":"1755_CR155","unstructured":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade | Nature Medicine. [cited 2023 Feb 1]. Available from: https:\/\/www.nature.com\/articles\/s41591-018-0041-7."},{"key":"1755_CR156","doi-asserted-by":"publisher","unstructured":"Frontiers | Improving the safety of cell therapy products by suicide gene transfer. [cited 2023 Feb 1]. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2014.00254\/full.","DOI":"10.3389\/fphar.2014.00254\/full"},{"key":"1755_CR157","doi-asserted-by":"crossref","unstructured":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy | Blood | American Society of Hematology. [cited 2023 Feb 1]. Available from: https:\/\/ashpublications.org\/blood\/article\/124\/8\/1277\/33527\/A-highly-compact-epitope-based-marker-suicide-gene.","DOI":"10.1182\/blood-2014-01-545020"},{"key":"1755_CR158","doi-asserted-by":"publisher","unstructured":"CAR T cells in solid tumors: challenges and opportunities | Stem Cell Research & Therapy | Full Text. [cited 2023 Feb 1]. Available from: https:\/\/stemcellres.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13287-020-02128-1.","DOI":"10.1186\/s13287-020-02128-1"},{"key":"1755_CR159","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"1755_CR160","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146:940\u20138 United States.","journal-title":"J Allergy Clin Immunol"},{"key":"1755_CR161","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. Journal of Hematology & Oncology. J Hematol Oncol. 2017;10:53.","journal-title":"J Hematol Oncol"},{"key":"1755_CR162","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1097\/01.HS9.0000848672.43673.8a","volume":"6","author":"F Locke","year":"2022","unstructured":"Locke F, Hu Z-H, Gerson J, Frank MJ, Budde LE, Wang M, et al. P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R\/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US). HemaSphere. 2022;6:1336.","journal-title":"HemaSphere"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01755-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:36:51Z","timestamp":1702168611000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01755-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":162,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01755-5","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}